| Quick answer |
|---|
| The best AI tools for clinical trial patient recruitment in 2026 are Deep 6 AI, now part of Tempus, for EHR cohort discovery, TriNetX for federated feasibility, and Inato for widening site selection. NIH’s TrialGPT is the only pipeline with peer-reviewed accuracy figures published. |
How we compare: on where the data lives, on whether the vendor has published evidence rather than marketing claims, and on what the tool does to demographic representation. None of the commercial platforms here publish list pricing, so this page does not guess at one.
Table of Contents
What these tools actually do
Recruitment for clinical trials fails on screening, not on advertising. The eligibility detail that disqualifies a patient — a prior line of therapy, a lab value, a comorbidity — usually sits in an unstructured clinical note that no ICD code captures. AI tools in this category read those notes.
That splits the market into three jobs. Cohort discovery searches your own records for patients who fit an open protocol. Feasibility and site selection asks which sites hold enough eligible patients to be worth opening. Patient-facing matching lets a patient screen themselves. Buying the wrong one of the three is the most common mistake in this category, and vendors rarely correct it during a demo. For agents that act across other jobs, see our guide to the best AI agents.
Best AI tools for clinical trial patient recruitment compared
| Tool | Primary job | Where the data sits | Published evidence |
|---|---|---|---|
| Deep 6 AI (Tempus) | Cohort discovery in your EHR | Provider network, post-Tempus merger | Vendor and press claims only |
| TriNetX | Feasibility and site selection | Federated — stays in each health system | Heavily cited in peer-reviewed literature |
| Inato | Site selection and diversification | Site marketplace | Vendor claims |
| Antidote | Patient-facing self-screening | Patient-supplied, direct to patient | Vendor claims |
| Paradigm | Community and oncology site enlistment | Network model | Vendor claims |
| TrialGPT | Criterion-level matching research | Runs against the public registry | Peer-reviewed accuracy and recall figures |
The evidence question nobody asks in the demo
Every vendor in this space quotes an enrolment lift. Almost none of those numbers come from a controlled comparison, and none of them are audited. Treat them as marketing until you see a method.
The exception is worth knowing about. NIH researchers published benchmark results for TrialGPT reporting a 42.6 per cent reduction in clinician screening time, recall above 90 per cent while reviewing only 6 per cent of the registry, and 87.3 per cent criterion-level accuracy against experienced clinicians on complex oncology criteria. Whether or not you use it, those are the numbers to hold a commercial vendor against. For analysing interviews and open-ended feedback, see our guide to AI qualitative research tools.
When a sales team quotes a figure, ask three questions: compared with what baseline, measured over how many protocols, and screened by whom. A tool that surfaces more candidates while lowering the pre-screen pass rate has moved work, not saved it.
Diversity targets change the buying criteria
FDORA requires sponsors of pivotal drug and certain device trials to submit a Diversity Action Plan setting enrolment goals by age, sex, race and ethnicity. The FDA published draft guidance in June 2024, and we found no final version published as of our September 2026 check — the statutory deadline passed in June 2025, and the submission requirement is to apply 180 days after final publication.
The planning consequence holds regardless of that timing. A recruitment tool that searches only large academic centres will reproduce the demographics of large academic centres. Site-diversification tools address that directly; EHR search tools do not, because they can only find patients already inside the network you gave them.
The tools in detail
Deep 6 AI (Tempus)
EHR-based cohort search that applies natural language processing to unstructured clinical notes, so patients are matched on details that never reach structured fields. Acquired by Tempus AI in March 2025; press coverage of the merged network cites roughly 30 million patient records across about 750 provider sites.
TriNetX
Federated real-world data network used for feasibility and site selection rather than individual matching. Data stays inside each health system and queries run against it, which sidesteps most data-transfer objections. Widely cited in the literature and consolidated further by its acquisition of Clinerion.
The product line is split rather than sold as one seat. Checked on 6 September 2026, the TriNetX solutions page lists TriNetX LIVE for exploring real-world data across a network it describes as more than 300 million global patients, separate licensed datasets drawn from over 150 million patients, the XetaBase genomic platform, the EVIDEX pharmacovigilance platform and a consulting arm. No price appears anywhere on that page — every route ends at a contact form, so scoping and cost are negotiated per engagement.
Inato
Site marketplace aimed at widening the pool beyond the same academic centres. Its models use disease incidence and site performance data to suggest sites a sponsor would not otherwise shortlist, which matters directly for geographic and demographic diversity targets.
Scale is the whole argument here. Checked on 6 September 2026, Inato’s sponsor page claims a network of more than 6,000 committed research sites across over 50 countries, alongside AI-assisted site selection, automated patient pre-screening and live enrolment tracking. Like the rest of the category it publishes no price and routes buyers to a demo request. Judge it on whether the sites it proposes are ones your CRO has never opened before — if the shortlist is the same twenty centres, the diversification premise has not been met.
Antidote
Patient-facing matching. Natural language processing structures eligibility criteria so a patient or carer can self-screen from a plain-language questionnaire, feeding direct-to-patient recruitment campaigns rather than site-side chart review.
Paradigm
Enlistment network, formerly Deep Lens, built to connect community oncology and non-academic sites to trials. Reported to have raised $203 million in early 2023, which makes it one of the better-funded independents in the category.
TrialGPT
A large language model matching pipeline published by NIH researchers, and the only option here with peer-reviewed benchmarks. Reported results include a 42.6 per cent reduction in clinician screening time, recall above 90 per cent while reviewing 6 per cent of the registry, and 87.3 per cent criterion-level accuracy. The NCBI TrialGPT project page is the primary source, and the underlying evaluation used three cohorts of 183 synthetic patients with more than 75,000 trial annotations — synthetic, which is the caveat to carry into any comparison with a live patient population.
How to run a shortlist
- Name the job first. Cohort discovery, feasibility, or patient-facing screening — one tool rarely does two of them well.
- Ask where the data moves. Federated query beats data extract for privacy review time, and privacy review is usually the longest pole in the deployment.
- Test on a closed protocol. Run the tool against a trial you have already completed and compare its shortlist against the patients you actually enrolled.
- Check the write-back. If matches cannot flow into your CTMS or EDC, coordinators will re-key them, and the time saving disappears.
For the research side of the same workflow, our roundup of AI medical research tools covers literature and evidence synthesis, AI agents for healthcare covers operational automation, and AI tools for academic research covers protocol and publication work.
Frequently Asked Questions
What are the best AI tools for clinical trial patient recruitment?
Deep 6 AI, now part of Tempus, is the strongest option for finding eligible patients inside your own EHR, and TriNetX is the standard for feasibility across a federated network. Inato widens site selection, Antidote handles patient-facing screening, and NIH’s TrialGPT is the only pipeline with published peer-reviewed accuracy figures.
Are AI recruitment tools compliant with HIPAA and GDPR?
Compliance sits with the sponsor and the site, not the vendor. Patient recruitment runs under HIPAA in the US, GDPR in Europe and IRB or ethics-committee oversight everywhere, so the questions to ask are whether identifiable data has to leave the health system, who signs the business associate or data-processing agreement, and whether patient-facing screening material has IRB approval. Federated designs such as TriNetX, where queries run inside each health system, shorten that review; tools that need a data extract lengthen it.
How do you check an AI recruitment tool for demographic bias?
Compare the demographic mix of the patients the model surfaces against the mix in the eligible population it searched — not against who ended up enrolled, which also reflects consent and site effects. Break it down by age, sex, race and ethnicity, the categories an FDA Diversity Action Plan uses, and repeat it per site. A tool that only searches large academic centres can pass that check on paper and still miss the community patients a diversity plan needs.
Do these tools integrate with your EHR and CTMS?
Unevenly, and it is the question that decides deployment time. Ask whether the platform reads your EHR directly, whether matches write back to the CTMS or EDC, and whether matching runs as a federated query or needs a data extract to leave your environment. If matches cannot flow into the CTMS, coordinators re-key them and most of the time saving disappears.
How much do AI patient recruitment tools cost?
None of the enterprise platforms in this category publish list pricing, so any figure you see quoted online is inferred rather than sourced. Expect annual contracts scoped by site count, trial count or record volume, and expect a separate data-use agreement. TrialGPT is the exception, published by NIH researchers as a research pipeline rather than a commercial product.
How long does an AI recruitment tool take to deploy?
The privacy and contracting review sets the timeline, not the software. A federated feasibility query can run once the data-use agreement is signed, because nothing leaves the health system. EHR-based cohort discovery needs the vendor connected to your clinical notes, a security review and usually an IRB-approved outreach plan before the first patient is contacted. Build in a closed-protocol test before go-live: it adds time, but it is the only way to see whether the shortlist resembles the patients you actually enrolled.
Conclusion
Pick by job, not by brand. If eligible patients are already inside your health system and you cannot find them, Deep 6 AI under Tempus is the strongest EHR search. If the question is which sites to open, TriNetX for feasibility and Inato for diversification answer it better. Antidote fits direct-to-patient campaigns, and Paradigm fits community oncology.
Then insist on evidence. TrialGPT’s published figures show what a defensible claim looks like in this category — a stated baseline, a stated dataset, and peer review. Anything quoted without those three is a number a vendor chose, and patient recruitment is too expensive a line item to buy on one.
